Watchlist Manager

Watchlist

Price: 9.63 CNY -2.63%

Market Cap: ¥2.3B

	Guiyang Xintian Pharmaceutical Co Ltd SZSE:002873	CN
	UFO Moviez India Ltd NSE:UFO	IN
B	Best Food Holding Company Ltd HKEX:1488	HK
	All for One Group SE XETRA:A1OS	DE
	AdvanSix Inc NYSE:ASIX	US
	Lincoln Pharmaceuticals Ltd NSE:LINCOLN	IN

Income Statement

Currency: CNY

	Dec-2016	Mar-2017	Jun-2017	Sep-2017	Dec-2017	Mar-2018	Jun-2018	Sep-2018	Dec-2018	Mar-2019	Jun-2019	Sep-2019	Dec-2019	Mar-2020	Jun-2020	Sep-2020	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024	Jun-2024	Sep-2024	Dec-2024	Mar-2025	Jun-2025	Sep-2025	Dec-2025
Revenue
Interest Expense	11	5	0	4	2	4	0	3	3	5	0	7	7	0	0	8	5	9	14	13	17	15	0	10	11	7	10	12	12	12	17	20	18	20	0	0	0
Revenue	633 N/A	641 +1%	665 +4%	680 +2%	682 +0%	691 +1%	677 -2%	678 +0%	694 +2%	700 +1%	739 +6%	762 +3%	773 +2%	712 -8%	711 0%	726 +2%	751 +3%	865 +15%	902 +4%	954 +6%	970 +2%	1 004 +4%	1 040 +4%	1 094 +5%	1 088 -1%	1 047 -4%	1 089 +4%	994 -9%	954 -4%	923 -3%	870 -6%	839 -4%	858 +2%	873 +2%	774 -11%	755 -2%	750 -1%
Gross Profit
Cost of Revenue	(115)	(127)	(133)	(141)	(133)	(149)	(154)	(156)	(146)	(160)	(168)	(172)	(163)	(162)	(163)	(168)	(166)	(200)	(204)	(215)	(201)	(223)	(234)	(255)	(248)	(254)	(268)	(244)	(219)	(225)	(224)	(228)	(231)	(260)	(232)	(227)	(217)
Gross Profit	518 N/A	514 -1%	532 +4%	539 +1%	549 +2%	542 -1%	523 -3%	523 0%	548 +5%	540 -1%	571 +6%	589 +3%	610 +4%	550 -10%	548 0%	558 +2%	585 +5%	665 +14%	698 +5%	739 +6%	769 +4%	781 +2%	806 +3%	839 +4%	840 +0%	793 -6%	821 +3%	750 -9%	735 -2%	697 -5%	646 -7%	611 -5%	627 +3%	614 -2%	542 -12%	528 -3%	533 +1%
Operating Income
Operating Expenses	(446)	(440)	(462)	(463)	(475)	(465)	(448)	(449)	(480)	(474)	(496)	(503)	(523)	(476)	(469)	(483)	(495)	(544)	(574)	(610)	(636)	(644)	(667)	(696)	(708)	(668)	(694)	(623)	(629)	(598)	(552)	(549)	(566)	(564)	(514)	(506)	(505)
Selling, General & Administrative	(427)	(431)	(460)	(461)	(451)	(471)	(450)	(442)	(446)	(454)	(469)	(476)	(500)	(460)	(461)	(486)	(479)	(537)	(562)	(597)	(616)	(630)	(656)	(683)	(684)	(652)	(676)	(599)	(592)	(567)	(511)	(511)	(520)	(524)	(479)	(466)	(456)
Research & Development	(14)	(6)	0	0	(23)	0	0	(9)	(32)	(19)	(26)	(25)	(21)	(18)	(14)	(7)	(13)	(13)	(17)	(20)	(19)	(23)	(20)	(21)	(21)	(22)	(26)	(32)	(37)	(39)	(47)	(45)	(38)	(44)	(39)	(43)	(38)
Depreciation & Amortization	(3)	(2)	0	0	(3)	0	0	0	(4)	0	0	0	(5)	0	0	0	(7)	0	0	0	(8)	0	0	0	(9)	0	0	0	(9)	0	0	0	(12)	0	0	0	(17)
Other Operating Expenses	(1)	(2)	(3)	(3)	1	6	2	3	1	(1)	(1)	(2)	3	3	6	10	5	6	5	6	7	9	9	8	6	6	9	8	8	9	6	7	5	4	4	2	7
Operating Income	72 N/A	74 +2%	70 -5%	76 +9%	74 -3%	76 +4%	75 -2%	74 -2%	68 -8%	66 -3%	75 +14%	86 +14%	87 +2%	74 -15%	79 +8%	75 -5%	90 +21%	122 +34%	124 +2%	129 +4%	132 +3%	137 +4%	139 +1%	142 +3%	132 -7%	126 -5%	127 +1%	127 +0%	105 -17%	99 -6%	94 -5%	62 -34%	61 -1%	50 -19%	28 -43%	22 -21%	28 +26%
Pre-Tax Income
Interest Income Expense	(11)	(10)	(10)	(8)	1	1	6	8	7	9	6	3	(4)	(4)	(6)	(9)	(4)	(12)	(13)	(12)	(15)	(16)	(10)	(10)	(10)	(12)	(17)	(18)	(11)	(13)	(18)	(21)	(17)	(19)	(14)	(11)	(17)
Non-Reccuring Items	0	(0)	0	0	1	1	1	1	(1)	0	0	0	(0)	0	0	0	(1)	0	(0)	(0)	(0)	0	(0)	(0)	(1)	0	0	0	(1)	0	0	19	18	19	18	(1)	(1)
Gain/Loss on Disposition of Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Other Income	3	4	8	7	(0)	(2)	(3)	(4)	7	6	4	4	(0)	(3)	(3)	(2)	(2)	(1)	(2)	(2)	(0)	(0)	1	1	(0)	(0)	(0)	(1)	(1)	(2)	(3)	(2)	(2)	(3)	(1)	(1)	(0)
Pre-Tax Income	64 N/A	68 +6%	68 +0%	74 +9%	75 +0%	77 +3%	80 +4%	79 -1%	81 +3%	82 +1%	85 +4%	93 +9%	83 -11%	67 -19%	71 +5%	65 -9%	84 +30%	109 +30%	109 +0%	116 +6%	117 +1%	121 +4%	129 +7%	133 +3%	121 -9%	113 -7%	110 -3%	108 -2%	92 -14%	85 -8%	73 -14%	58 -21%	61 +5%	47 -23%	31 -34%	9 -70%	10 +7%
Net Income
Tax Provision	(7)	(8)	(6)	(7)	(9)	(9)	(10)	(10)	(11)	(11)	(12)	(18)	(12)	(11)	(10)	(2)	(10)	(13)	(14)	(13)	(16)	(15)	(18)	(17)	(10)	(3)	(5)	(9)	(12)	(13)	(8)	(4)	(8)	(6)	(3)	(2)	(1)
Income from Continuing Operations	57	61	62	67	66	68	69	69	70	71	73	75	71	57	61	63	74	96	96	102	101	106	111	117	112	110	105	99	81	71	65	54	52	41	28	8	9
Income to Minority Interest	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income (Common)	57 N/A	61 +6%	62 +2%	67 +9%	66 -2%	68 +3%	69 +2%	69 N/A	71 +2%	71 +0%	73 +3%	76 +3%	71 -6%	57 -20%	62 +8%	63 +2%	74 +18%	96 +30%	96 -1%	102 +6%	101 -1%	106 +5%	111 +5%	117 +5%	112 -4%	110 -1%	105 -5%	99 -6%	81 -18%	71 -12%	65 -9%	54 -17%	52 -3%	41 -22%	28 -32%	8 -73%	9 +21%
EPS (Diluted)	0.65 N/A	0.69 +6%	0.62 -10%	0.57 -8%	0.63 +11%	0.57 -10%	0.59 +4%	0.59 N/A	0.61 +3%	0.6 -2%	0.62 +3%	0.65 +5%	0.62 -5%	0.5 -19%	0.48 -4%	0.51 +6%	0.6 +18%	0.78 +30%	0.39 -50%	0.4 +3%	0.41 +2%	0.43 +5%	0.45 +5%	0.47 +4%	0.46 -2%	0.47 +2%	0.44 -6%	0.35 -20%	0.33 -6%	0.27 -18%	0.28 +4%	0.23 -18%	0.24 +4%	0.17 -29%	0.11 -35%	0.02 -82%	0.04 +100%

Income Statement Balance Sheet Cash Flow Statement

Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873

Income Statement

Earnings Waterfall
Guiyang Xintian Pharmaceutical Co Ltd

Income Statement
Guiyang Xintian Pharmaceutical Co Ltd

See Also

Company

Help

Tools

Stocks

Guiyang Xintian Pharmaceutical Co Ltd SZSE:002873

Income Statement

Earnings Waterfall Guiyang Xintian Pharmaceutical Co Ltd

Income Statement Guiyang Xintian Pharmaceutical Co Ltd

See Also

Company

Help

Tools

Stocks

Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873

Earnings Waterfall
Guiyang Xintian Pharmaceutical Co Ltd

Income Statement
Guiyang Xintian Pharmaceutical Co Ltd